Evaluation of pyrosequencing for extensive drug resistance-defining anti-tuberculosis drugs for use in public healthcare
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Tuberculosis
- Vol. 110, 86-90
Abstract
No abstract availableKeywords
Funding Information
- Mycobacteriology section of the Department of Microbiology
This publication has 14 references indexed in Scilit:
- A standardised method for interpreting the association between mutations and phenotypic drug resistance inMycobacterium tuberculosisEuropean Respiratory Journal, 2017
- Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant TuberculosisPLOS ONE, 2015
- Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assayTuberculosis, 2015
- Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden CountriesAntimicrobial Agents and Chemotherapy, 2015
- Pyrosequencing for Rapid Detection of Extensively Drug-Resistant Mycobacterium tuberculosis in Clinical Isolates and Clinical SpecimensJournal of Clinical Microbiology, 2014
- 50 years of tuberculosis control in India: Progress, pitfalls and the way forwardIndian Pediatrics, 2013
- Tuberculosis: Current situation, challenges and overview of its control programs in IndiaJournal of Global Infectious Diseases, 2011
- Pyrosequencing for Rapid Detection of Mycobacterium tuberculosis Resistance to Rifampin, Isoniazid, and FluoroquinolonesJournal of Clinical Microbiology, 2009
- Prevalence of and Molecular Basis for Tuberculosis Drug Resistance in the Republic of Georgia: Validation of a QIAplex System for Detection of Drug Resistance-Related MutationsAntimicrobial Agents and Chemotherapy, 2008
- Bias, prevalence and kappaJournal of Clinical Epidemiology, 1993